Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + venetoclax with ATRA or placebo in AML ineligible for induction
DRKS00023646Phase 3Recruiting
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Decitabine + venetoclax + ATRA with Decitabine + venetoclax + placebo (2 arms). Started Aug 2022; status: recruiting.
02
Drugs
decitabinevenetoclaxtretinoin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on DRKS00023646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00023646.